Closed · HT942526BCRPBTA12 · CFDA 12.420 · Discretionary

DoW Breast Cancer, Breakthrough Award Levels 1 and 2

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
July 8, 2026
Close date
18
Expected awards

The verdict

DoW Breast Cancer, Breakthrough Award Levels 1 and 2 is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 18 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
18
expected awards
12.420
CFDA program

Recently closed NOFO

This listing closed on July 8, 2026. CFDA 12.420 may re-announce under a new opportunity number. Historical award band was Varies by applicant.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 8, 2026

Posted May 4 Closes Jul 8

Est. Total Funding

$31,800,000

Expected Awards

18

Instrument

Grant

Description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2.Distinctive Features:· This funding mechanism allows for applications submitted under Funding Level 1 or Funding Level 2. Funding Level 2 also includes a Population Science Studies option. With compelling justification, population science studies may request higher levels of funding and an additional year in the period of performance.· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Catch-all / unrestricted eligibility mark · HT942526BCRPBTA12

Grants.gov marks DoW Breast Cancer with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

More from Defense Health Agency Contracting Activity - DHACA

Closed Closed September 22, 2026

DoW Neurofibromatosis Synergistic Idea Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Investigator-Initiated Research Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Research Academy – Scholar Award

View →
Closed Closed September 22, 2026

DoW Neurofibromatosis Exploration-Hypothesis Development Award

View →
Open Closes November 18, 2026

DOW Combat Readiness – Medical Research Program Translational Research Award

View →

What to do next

DoW Breast Cancer is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants